Press Releases

16.08.2018

• Term sheet: Global assignment and co-development agreement for lead compound lefitolimod • Substantial potential payments in milestones and in addition royalties – near-term consideration of €23 million • Pivotal IMPALA study with lefitolimod...

09.08.2018

• Ongoing clinical studies with lefitolimod on track, new studies in preparation • License and development cooperation agreement signed with ONCOLOGIE; initial revenues generated under license agreement • Dr Ignacio Faus new Chief...

01.08.2018

Berlin, August 1, 12018 – The Supervisory Board of biopharmaceutical Company MOLOGEN AG appointed Dr Ignacio Faus as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from August 1, 2018.

11.06.2018

• Shareholders agree to all draft proposals with large majority • Reverse stock split ratio of 5:1 • Generation of new capital

   

Displaying results 1 bis 7 von 20

Page 1

Page 2

Page 3

next

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.